BTF acquired by bioMerieux
Australian company BTF Decisive Microbiology has been acquired by bioMerieux. French clinical diagnostics company bioMérieux is present in more than 150 countries through 35 subsidiaries and has a large network of distributors.
The new acquisition will make BTF's products more accessible to a wider distribution network.
Initially, BTF will operate as a standalone subsidiary, so all existing customers will not see any changes in the short term. BTF's contact details remain unchanged.
Noxopharm appoints Dr Olivier Laczka CEO
Australian clinical-stage biotech company Noxopharm Limited has appointed Dr Olivier Laczka as...
Nominations now open for the 2026 NMI Measurement Awards
Until 20 May, the National Measurement Institute (NMI) is accepting nominations for the 2026 NMI...
Australia to begin treaty negotiations on association to Horizon Europe
To give Australian organisations access to the world's largest pooled research fund in 2027,...
